Tag Archives: drug development

BIO Releases Largest Study Ever on Clinical Development Success Rates


On Wednesday, BIO released the largest ever study of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success. “This study provides a wealth of information about drug development success rates Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

ICYMI: John Lechleiter: An Empty Obama-Clinton-Sanders Plan on Drug Costs

Wall Street Journal

Writing in the Wall Street Journal today, Eli Lilly and Company Chairman, President and CEO John Lechleiter examines proposals that would require pharmaceutical companies to disclose detailed information about the cost of R&D for individual drugs and the extent of discounts offered to insurers for each drug. Such proposals have been advanced in President Obama’s budget and on the campaign trail by Bernie Sanders and Hillary Clinton. But as Lechleiter explains, the key numbers are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Integrating the Patient Voice: Recap of the 2016 BIO CEO & Investor Conference

CEO2013_115x75_Thumbnail copy

The 2016 BIO CEO & Investor Conference isn’t just for biotech companies and the investment community, the conference featured a strong patient voice and focus on the patient perspective in drug development and drug delivery. Two of the most highly-attended panel discussions were moderated by patient advocates. On Monday, Sue Peschin, President & Chief Executive Officer, Alliance for Aging Research, led a timely panel discussion with clinical researchers and biotech CEOs around the recent positive Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Setting the Record Straight on Innovation and Drug Development


Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, researchers and investors working in this field have firmly established themselves at the forefront of medical innovation and the search for new cures and therapies for previously untreatable diseases. That’s why it is important that policy proposals designed to respond to the activities of outliers like Turing Pharmaceuticals and Valeant do not hurt America’s leadership in biotechnology innovation and investment. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Expanding the Role of Patients in Drug Development


Working alongside scientists, universities, and biotech companies, patients and patient organizations have the ability to play a critical role in the search for treatments and cures for chronic and deadly diseases.  As part of the 5th authorization of the Prescription Drug User Fee Act (PDUFA V), the Food and Drug Administration made a commitment to more systematically gather patients’ perspectives on their condition and the available therapies in order to incorporate these findings into their Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,